Ascendis Pharma A/S

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ASND and other ETFs, options, and stocks.

About ASND

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. 

CEO
Jan Møller Mikkelsen
CEOJan Møller Mikkelsen
Employees
Employees
Headquarters
Hellerup, Capital Region
HeadquartersHellerup, Capital Region
Founded
2006
Founded2006
Employees
Employees

ASND Key Statistics

Market cap
15.04B
Market cap15.04B
Price-Earnings ratio
-58.64
Price-Earnings ratio-58.64
Dividend yield
Dividend yield
Average volume
936.16K
Average volume936.16K
High today
$250.00
High today$250.00
Low today
$241.06
Low today$241.06
Open price
$246.14
Open price$246.14
Volume
318.46K
Volume318.46K
52 Week high
$250.74
52 Week high$250.74
52 Week low
$150.89
52 Week low$150.89

Stock Snapshot

Ascendis Pharma A/S(ASND) stock is priced at $241.13, giving the company a market capitalization of 15.04B. It carries a P/E multiple of -58.64.

On 2026-05-08, Ascendis Pharma A/S(ASND) stock moved within a range of $241.06 to $250.00. With shares now at $241.13, the stock is trading +0.0% above its intraday low and -3.5% below the session's peak.

Trading activity shows a volume of 318.46K, compared to an average daily volume of 936.16K.

Over the past 52 weeks, Ascendis Pharma A/S(ASND) stock has traded between a high of $250.74 and a low of $150.89.

Over the past 52 weeks, Ascendis Pharma A/S(ASND) stock has traded between a high of $250.74 and a low of $150.89.

ASND News

TipRanks 8h
Ascendis Pharma price target lowered to $326 from $330 at Wells Fargo

Wells Fargo lowered the firm’s price target on Ascendis Pharma (ASND) to $326 from $330 and keeps an Overweight rating on the shares. The firm notes Yorvipath i...

TipRanks 9h
Analyst Reiterates Buy on Robust Rare Endocrine Portfolio and Pipeline Progress as Price Target Nudged to $288 on Higher Share Count

Ascendis Pharma, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tazeen Ahmad from Bank of America Securities reiterate...

TipRanks 1d
Ascendis Pharma Swings to €629 Million Q1 2026 Profit on Strong Revenue Growth

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Analyst ratings

100%

of 17 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own ASND. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.